ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ixekizumab

Also written as “Ixekizumab”, “LY2439821” and “80 mg ixekizumab”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylarthritis · Arthritis, Rheumatoid · Axial Spondyloarthritis, led by 3 companies.

Drug pageIxekizumab: every studyAll 56 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 4, 201738 company-led studies, 3 open or runningNext primary completion: Jun 9, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly361 open or runningphase 4since May 4, 2017Aug 25, 2009none ahead
Celltrionits history only11 open or runningphase 1since Sep 23, 2025Sep 23, 2025none ahead
Samsung Bioepisits history only11 open or runningphase 1since Aug 20, 2026Aug 20, 2026Jun 9, 2027phase 1 · NCT07789964

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Aug 25, 2009.

  1. Apr 28, 2016Phase 3 study in Axial SpondyloarthritisNCT02757352 · 303 enrolled · United States, Argentina, Austria and more
  2. Dec 13, 2016Phase 1 study in PsoriasisNCT02993471 · 28 enrolled · United States
  3. Mar 3, 2017Phase 1 study in PsoriasisNCT03073213 · 32 enrolled · China
  4. Mar 3, 2017Phase 3 study in Plaque PsoriasisNCT03073200 · 201 enrolled · United States, Argentina, Canada and more
  5. Apr 3, 2017Phase 3 study in Axial SpondyloarthritisNCT03129100 · 773 enrolled · United States, Argentina, Austria and more
  6. May 4, 2017Phase 4 study in Arthritis, PsoriaticNCT03151551 · 566 enrolled · Argentina, Australia, Austria and more
  7. Nov 9, 2017Phase 3 study in Skin DiseasesNCT03364309 · 438 enrolled · China
  8. Jun 20, 2018Phase 4 study in Plaque PsoriasisNCT03573323 · 1,027 enrolled · United States, Canada, Puerto Rico
  9. Feb 19, 20192 phase 1 studies in HealthyNCT03848416, NCT03848403
  10. May 7, 2019Phase 4 study in PsoriasisNCT03942042 · 12 enrolled · Japan
  11. Feb 5, 2020Phase 1 study in HealthyNCT04259346 · 245 enrolled · United States
  12. Feb 19, 2020Phase 3 study in SpondylarthritisNCT04285229 · 147 enrolled · China
  13. Aug 24, 2020Phase 3 study in Arthritis, JuvenileNCT04527380 · 101 enrolled · Argentina, Belgium, Czechia and more
  14. May 4, 2023Phase 4 study in Arthritis, PsoriaticNCT05855967 · 250 enrolled · India

TargetBeta

IL17A →read by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
secukinumabruleNovartisphase 4128
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
simepdekinraEli Lillyphase 27
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

All 36 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05855967Arthritis, Psoriatic · India4CompletedAug 8, 2024250
NCT04527380Arthritis, Juvenile · Argentina, Belgium, Czechia and more3Active, not recruitingFeb 19, 2024101
NCT04285229Spondylarthritis · China3CompletedMar 31, 2021147
NCT04259346Healthy · United States1CompletedFeb 19, 2021245
NCT03942042Psoriasis · Japan4CompletedJul 22, 202012
NCT03848416Healthy · United States1CompletedJun 7, 201999
NCT03848403Healthy · United States1TerminatedJul 18, 201970
NCT03573323Plaque Psoriasis · United States, Canada, Puerto Rico4CompletedJul 15, 20191,027
NCT03364309Skin Diseases · China3CompletedJun 4, 2020438
NCT03151551Arthritis, Psoriatic · Argentina, Australia, Austria and more4CompletedNov 15, 2018566
NCT03129100Axial Spondyloarthritis · United States, Argentina, Austria and more3CompletedMay 26, 2020773
NCT03073213Psoriasis · China1CompletedMay 14, 201932
NCT03073200Plaque Psoriasis · United States, Argentina, Canada and more3CompletedFeb 7, 2019201
NCT02993471Psoriasis · United States1CompletedNov 21, 201728
NCT02757352Axial Spondyloarthritis · United States, Argentina, Austria and more3CompletedMar 1, 2019303
NCT02718898Psoriasis · United States, Australia, Austria and more3CompletedFeb 22, 2017149
NCT02696798Spondylarthritis · United States, Argentina, Brazil and more3CompletedMay 18, 2018316
NCT02696785Spondylarthritis · United States, Czechia, Germany and more3CompletedDec 8, 2017341
NCT02634801Plaque Psoriasis · Germany3CompletedNov 29, 2016162
NCT02584855Arthritis, Psoriatic · United States, Bulgaria, Czechia and more3CompletedOct 30, 2018394
NCT02561806Plaque Psoriasis · Austria, Belgium, Canada and more3CompletedMay 2016302
NCT02543918Healthy · United States1CompletedNov 201584
NCT02513550Plaque Psoriasis · United States, Argentina, Australia and more3CompletedNov 20161,257
NCT02387801Psoriasis · United States3CompletedSep 201512
NCT02349295Arthritis, Psoriatic · United States, Australia, Czechia and more3CompletedSep 9, 2016363
NCT01870284Spondylitis, Ankylosing · United States, Argentina, Belgium and more3WithdrawnApr 20160
NCT01777191Plaque Psoriasis · United States, Puerto Rico3CompletedMay 2014204
NCT01695239Arthritis, Psoriatic · United States, Belgium, Bulgaria and more3CompletedDec 2014417
NCT01646177Psoriasis · United States, Argentina, Bulgaria and more3CompletedMay 22, 20141,346
NCT01624233Psoriasis · Japan3CompletedSep 201391
NCT01597245Psoriasis · United States, Australia, Austria and more3CompletedMar 25, 20141,224
NCT01474512Psoriasis · United States, Australia, Canada and more3CompletedJun 24, 20141,296
NCT01253265Arthritis, Rheumatoid · Japan1CompletedDec 201132
NCT01236118Arthritis, Rheumatoid · Japan1CompletedJan 201328
NCT01107457Psoriasis · United States, Denmark2CompletedJan 2011142
NCT00966875Arthritis, Rheumatoid · United States, Argentina, Chile and more2CompletedMar 2011448

How it is read

Names in the registry

  • “Ixekizumab”, 29 entries
  • “LY2439821”, 3 entries
  • “80 mg ixekizumab”, 2 entries
  • “Ixekizumab 80 mg Q4W”, 1 entry
  • “Ixekizumab 80 mg Q2W”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.